NCEL
NewcelX Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
NewcelX Ltd.
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
NewcelX Ltd.
2.41
−0.23 · −8.71%
post 2.71 +12.45%
No changes.
No changes.
Annual filing, covered
20-F parsed · Apr 29 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Apr 29 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
—
—
| Manager | Value | % base | |
|---|---|---|---|
| HRT Financial | $41,000 | 94.05% | new |
| Jones Financial Companies Lllp | $2,548 | 5.85% | new |
| Caitong International | $33 | 0.08% | +800.00% |
| CoreCap | $11 | 0.03% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| HRT Financial | $41,000 | 94.05% | new |
| Jones Financial Companies Lllp | $2,548 | 5.85% | new |
| Caitong International | $33 | 0.08% | +800.00% |
| CoreCap | $11 | 0.03% | 0.00% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for NewcelX Ltd..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for NewcelX Ltd..
Tall tick = annual report · Source: EDGAR
Linked news